Every case starts at the same point
The Advanced Lipid block opens each case in the same place: a patient on maximum tolerated statin therapy, still above target. That is deliberate. Everything before that point is covered in the prevention track, and it is the decision after it that separates competent lipid management from a repeated dose increase.
These 349 pages are the set text for that block.
How the modules progress
First, whether the residual risk is lipid-driven at all — a question learners routinely skip. Then measurement, including when apoB is the better number and when a lipoprotein(a) result changes a plan. Then agent sequencing: ezetimibe, PCSK9 inhibition, bempedoic acid, inclisiran, ordered by evidence rather than by recency.
The intolerance module
Runs differently from the rest. Learners are given a patient reporting muscle symptoms and must decide whether to stop, rechallenge or investigate — and the module then presents the nocebo data from the blinded rechallenge trials. It reliably changes how a cohort handles statin intolerance afterwards.
Also covered
Hypertriglyceridaemia and pancreatitis risk. Familial hypercholesterolaemia and cascade screening. Lipids in kidney disease, diabetes and pregnancy.
Prerequisite
The prevention track or equivalent. Learners without it find the cases start beyond them, which is by design.
PDF, 349 pages, lifetime access from CardiologyBooks.com.






Reviews
There are no reviews yet.